Damora Therapeutics (DMRA) Current Assets (2019 - 2026)
Damora Therapeutics' (DMRA) quarterly Current Assets came in at $535.4 million in Q1 2026, up 3493.29% YoY from $14.9 million in Q1 2025, and up 105.59% on a QoQ basis from $260.4 million in Q4 2025.
Damora Therapeutics (DMRA) Current Assets (2019 - 2026) Analysis & Trends
Damora Therapeutics (DMRA) has 8 years of Current Assets data on file, last reported at $535.4 million in Q1 2026.
- Quarterly Current Assets rose 3493.29% year-over-year to $535.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $535.4 million (up 3493.29% YoY) and the FY2025 annual result came in at $260.4 million, up 1450.14% from the prior year.
- Current Assets grew to $535.4 million in Q1 2026, from $260.4 million in the prior quarter.
- In the past five years, Current Assets ranged from a high of $535.4 million in Q1 2026 to a low of $9.8 million in Q3 2025.
- A 5-year average of $84.6 million and a median of $47.1 million in 2023 frame the typical range for Current Assets.
- Annual changes were most pronounced in 2024 — Current Assets slumped 54.95% — and 2026, when it surged 3493.29%.
- Tracing DMRA's Current Assets over 5 years: stood at $63.9 million in 2022, then plunged by 42.45% to $36.8 million in 2023, then sank by 54.32% to $16.8 million in 2024, then jumped by 1450.14% to $260.4 million in 2025, then surged by 105.59% to $535.4 million in 2026.
- The last three Current Assets figures came in at $535.4 million (Q1 2026), $260.4 million (Q4 2025), and $9.8 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 12.54 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 18.45 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 8.07 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 4.03 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 7.22 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 11.83 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 1.76 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 4.62 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 1.63 Bn |
| 10 | Damora Therapeutics | 1.92 Bn | 1.38 Bn | - | 543.60 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 543.60 Mn |
| Mar 31, 2026 | 535.40 Mn |
| Dec 31, 2025 | 260.42 Mn |
| Sep 30, 2025 | 9.80 Mn |
| Jun 30, 2025 | 13.03 Mn |
| Mar 31, 2025 | 14.90 Mn |
| Dec 31, 2024 | 16.80 Mn |
| Sep 30, 2024 | 21.20 Mn |
| Jun 30, 2024 | 25.20 Mn |
| Mar 31, 2024 | 30.50 Mn |
| Dec 31, 2023 | 36.77 Mn |
| Sep 30, 2023 | 47.05 Mn |
| Jun 30, 2023 | 55.40 Mn |
| Mar 31, 2023 | 57.10 Mn |
| Dec 31, 2022 | 63.90 Mn |
| Sep 30, 2022 | 71.20 Mn |
| Jun 30, 2022 | 82.20 Mn |
| Mar 31, 2022 | 97.03 Mn |
| Dec 31, 2021 | 110.10 Mn |
| Sep 30, 2021 | 107.00 Mn |